^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ER (Estrogen receptor)

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
    1m
    An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy. (PubMed, Front Oncol)
    Moreover, this "Breast HERV19" expression signature was associated with better prognosis in HR+HER2- eBC, in which its expression was also correlated with biomarkers of sensitivity to anti PD-1 immunotherapy, such as tumor-infiltrating lymphocytes (TILs), PD-L1, and estrogen receptor (ER) expression levels. In eBC, our "Breast HERV19" expression signature makes it possible to isolate a subgroup of HR+HER2- tumors presenting strong immunogenicity, better prognosis, and biological characteristics that suggest a possible benefit from immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor)
    |
    HER-2 negative • HER-2 expression
    1m
    Development and validation of a machine learning model to evaluate survival in patients with newly diagnosed breast cancer with liver metastasis. (PubMed, Front Oncol)
    The calibration curves indicated good agreement and DCA confirmed the clinical utility of the model. The proposed nomogram demonstrated robust predictive performance for patients with breast cancer and liver metastases and may provide valuable prognostic information, pending further validation.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    1m
    High Mammographic Density in Younger Women and Its Implications for Breast Cancer Subtypes. (PubMed, Int J Breast Cancer)
    These underscore the relevance of age-related biological factors in shaping breast cancer characteristics. However, among Indonesian women over 45 years old, the proportion of high breast density remains remarkably high (65.6%), suggesting that factors beyond age-such as genetic, hormonal, or lifestyle influences-may contribute to the persistence of dense breast tissue in this population.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 expression • ER negative
    1m
    Ultrasound-Based AI in Predicting Hormone Receptor Status in Breast Cancer: Is "Digital Biopsy" Possible. (PubMed, J Imaging Inform Med)
    This approach offers a promising, non-invasive alternative to traditional tissue sampling by enabling a "digital biopsy." Integrating these models into clinical workflows could reduce the diagnostic burden on patients and facilitate personalized treatment planning. However, further validation in larger, prospective cohorts is necessary.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive
    1m
    Planetary Health Diet Index and breast cancer risk. (PubMed, Br J Cancer)
    Adhering to a diet that supports both human and planetary health was associated with lower breast cancer risk, particularly ER-negative tumors. Strategies to reduce breast cancer incidence should emphasize the win-win opportunities for a high planetary health diet.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER negative
    1m
    Spatial Transcriptomic Dissection of the Cellular and Molecular Architecture of Fear Memory and its Association with Memory Function. (PubMed, Curr Neuropharmacol)
    This study provides a spatially resolved characterization of cellular composition, intercellular communication, and molecular regulation associated with FM. The findings generate new hypotheses regarding the relationship between emotional regulation and memory function, particularly the possibility that FM formation and consolidation compromise general memory processes. Collectively, these results offer new insights into the cellular and molecular neurobiology of FM.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • NCAM1 (Neural cell adhesion molecule 1)
    1m
    Comprehensive CYP2D6 genotyping improves phenotype classification and highlights methodological pitfalls in tamoxifen-treated breast cancer. (PubMed, BMC Cancer)
    Comprehensive CYP2D6 profiling improves phenotype assignment and highlights methodological pitfalls that may contribute to inconsistencies in pharmacogenetic studies. While no definitive association with clinical outcomes was observed in the overall cohort, these findings underscore the importance of analytically robust genotyping strategies and warrant validation in larger, prospectively designed cohorts, and highlight the importance of comprehensive genotyping strategies in resolving inconsistencies across pharmacogenetic studies.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    tamoxifen
    1m
    TBCRC026: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jun 2026 --> Jun 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    1m
    Synthesis of meta-substituted phenols and 1-estradiol conjugated analogues of suberoylanilide hydroxamic acid (SAHA). (PubMed, Org Biomol Chem)
    Unfortunately, the preliminary bioactivity test showed low activity and selectivity toward breast cancer cell lines. Structural optimization or a more appropriate selection of the bioactive group to be conjugated would be required.
    Journal
    |
    ER (Estrogen receptor)
    |
    Zolinza (vorinostat)
    1m
    VALD-3 Induces GSDME-Dependent Pyroptosis via ROS/JNK/Bax Pathway in Triple-Negative Breast Cancer Cells. (PubMed, Biochem Genet)
    Thus, VALD-3 treatment initiated the ROS/JNK/Bax-mitochondrial apoptosis pathway, leading to caspase-3 activation and GSDME cleavage, thereby executing pyroptosis. These findings suggest that GSDME-dependent pyroptosis is a novel mechanism by which VALD-3 eradicates cancer cells and offer new insights into potential clinical applications for anticancer therapies.
    Journal
    |
    ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • GSDME (Gasdermin E)
    |
    ER positive
    1m
    Genetic regulatory axis between AGR2 and ESR1 promotes breast cancer progression. (PubMed, PLoS One)
    Integration with publicly available epigenomic datasets further supports a potential regulatory connection between ERα-associated chromatin landscapes and AGR2 expression. Together, these findings define AGR2-dependent transcriptional networks in breast cancer and identify ESR1-associated signaling as a key pathway perturbed upon AGR2 loss, providing a foundation for future mechanistic studies targeting this regulatory interaction.
    Journal
    |
    ER (Estrogen receptor) • AR (Androgen receptor) • CDH1 (Cadherin 1) • AGR2 (Anterior gradient 2) • CD55 (CD55 Molecule) • S100P (S100 calcium binding protein P)
    1m
    A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. (PubMed, PLoS One)
    Collectively, network analysis suggests that phytochemicals in Vernolac may exert anticancer effects through multiple cancer-related pathways, including those associated with apoptosis, immune modulation, oxidative stress, inflammation, and cell proliferation. Furthermore, the identified targets and enriched pathways suggest a potential role in modulating drug resistance and treatment response, providing a computational basis for its application as an adjunct to conventional cancer therapies and warranting further investigation in preclinical and clinical settings.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IL6 (Interleukin 6) • CDK4 (Cyclin-dependent kinase 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)